Press Releases

AVROBIO, Inc. Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass. , June 20, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose, today announced the pricing of its

Read More »

AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases

Company to initiate Phase 2 trial with lead gene therapy, AVR-RD-01, based on promising initial clinical data in Fabry disease Strong investor syndicate supports multi-product portfolio with three additional gene therapies for Gaucher disease, cystinosis and Pompe disease Cambridge, Mass., February

Read More »